Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Salem, VA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Salem, VA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New Haven, CT
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Springfield, IL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Urbana, IL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Urbana, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ames, IA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ames, IA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Baton Rouge, LA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Duluth, MN
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Albany, NY
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Middletown, OH
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
mi
from
La Roche Sur Yon,
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
mi
from
La Roche Sur Yon,
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Huntsville, AL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fayetteville, AR
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
La Jolla, CA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Denver, CO
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Athens, GA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Macon, GA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Thomasville, GA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Thomasville, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Harvey, IL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Harvey, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Kansas City, KA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Louisville, KY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Boston, MA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Farmington Hills, MI
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Kalamazoo, MI
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lansing, MI
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bolivar, MO
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bolivar, MO
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Basking Ridge, NJ
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cherry Hill, NJ
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Voorhees, NJ
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Commack, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Commack, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fresh Meadows, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Rochester, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sleepy Hollow, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Allentown, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials